We analyzed biotech funding data on our online biopharmIQ platform to identify companies who had early-stage (Angel/Pre-Seed, Seed, Series A round) biotech funding events from Q1 to Q3 of 2024. To identify biotech funding events, every workday, our team uses a combination of automated and manual systems. With respect to countries with the most companies with $1M+ early-stage funding events in Q1 to Q3 of 2024 (FIG. 1), not surprisingly the U.S. (141 companies) was at the top of the list for these types of funding events that were captured by our systems.
However, there were some surprises in the data. We were a bit surprised to see the UK (25 companies) and China (21 companies) had almost 1/5 as many companies as the U.S. with $1M+ funding events in Q1 to Q3 of 2024. And more surprised that Switzerland (14 companies) came up next on the list. We were surprised that Canada (11 companies) had more companies in this category as France (9 companies).
FIG. 1. Number of biotech companies with $1M+ (U.S. dollars/equivalent) early-stage funding events worldwide in Q1 to Q3 2024
Finally, with respect to the United States (FIG. 2), not surprisingly when we analyzed the data from our powerful online biopharmIQ platform, California and Massachusetts led with 44 and 37 companies, respectively, that had a $1M+ early round funding event in Q1 to Q3 of 2024. Perhaps more surprising is that New York (12 companies) had 4x as many companies as Pennsylvania (3 company). Of course, over a longer period of time these surprising nuances likely would correct themselves.
FIG. 2. Number of biotech companies with $1M+ (U.S. dollars/equivalent) early-stage funding events in the U.S. in Q1 to Q3 of 2024.
You can check out recent funding data on our online biopharmIQ platform. Want to see our online platform in action? Watch a short demo video of our platform. Get instant access to all our data/modules: Check out our affordable pricing plans, which come with a satisfaction guarantee.
Have questions or want to schedule an online demo?
Contact marketing@biopharmIQ.com.
***
Article History:
10/02/24 MV/RF
10/03/24 RF (Updated data)
Not legal, investing, or tax advice.
Comments